Fate Therapeutics Inc (FATE)

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics

Benzinga

Wall Street Breakfast: The Week Ahead

Seeking Alpha

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

GlobeNewswire Inc.

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

GlobeNewswire Inc.

How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?

Zacks Investment Research

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

Zacks Investment Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

Zacks Investment Research

Novartis (NVS) to Report Q1 Earnings: What to Expect?

Zacks Investment Research

What's in Store for Biogen (BIIB) This Earnings Season?

Zacks Investment Research

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

Zacks Investment Research

Where Fate Therapeutics Stands With Analysts

Benzinga

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

Zacks Investment Research

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?

Zacks Investment Research

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

Zacks Investment Research

Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

GlobeNewswire Inc.

Evaluating Fate Therapeutics: Insights From 5 Financial Analysts

Benzinga

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Fate Therapeutics to Present at Upcoming March Investor Conferences

GlobeNewswire Inc.

Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics

Benzinga

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Zacks Investment Research

Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

GlobeNewswire Inc.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks Investment Research

Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks Investment Research

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire Inc.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?

Zacks Investment Research

Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga

Fate Therapeutics (FATE) Upgraded to Buy: Here's Why

Zacks Investment Research

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?

Zacks Investment Research

Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging

Zacks Investment Research

Philips (PHG) Bolsters Diagnostic Imaging With New Launches

Zacks Investment Research

Philips (PHG) Adds BlueSeal to its Diagnostic Imaging Portfolio

Zacks Investment Research

Analyst Ratings for Fate Therapeutics

Benzinga

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

GlobeNewswire Inc.